Regulations on new drugs, drug prices, and other aspects of the Japan's pharmaceutical industry had in effect protected domestic manufacturers and kept them from inventing a truly innovative new drug. As the deregulation and the international harmonization of the drug market proceed, disintegrated Japanese drug makers will need to ally or integrate with partners in and out of the industry.

M&A will have a positive effect on the marketing, but not necessarily on the research. Possible increase of university TLO and spinouts in Japan can improve the access to the information in Japanese universities, but the access is open to both domestic and international companies. Alliances between drug makers and the local parties with an international competitive edge, such as electronics and precision mechanics, may produce a unique synthesis.

Atsuomi Obayashi is currently a visiting scholar at Stanford University's Asia/Pacific Research Center and associate professor at the Keio University Graduate School of Business Administration. His research topics include application of the game theory, the contract theory and economics of the R&D. He received his Ph. D. in public policy from the University of Chicago in 1996 and an LL.B. from Kyoto University, Japan, in 1983.